Get notified when SKYE files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Going Concern (new) — Auditor now expresses substantial doubt about the company's ability to continue as a going concern due to recurring losses and insufficient cash runway.
Skye Bioscience reports Phase 2a miss, pivots to combination therapy as cash runs out Q4 2026
Filed March 10, 2026 · Period ending December 31, 2025 · Compared to 10-K Mar 20, 2025 · ~2 min read
Key Changes
-
high
Auditor issued going-concern opinion citing substantial doubt about ability to continue operations; cash of $25.7M funds operations only through Q4 2026, excluding Phase 2b costs. Company warns it may need to consider bankruptcy if liquidity doesn't improve.
Risk Factors & MD&A verify on EDGAR → -
high
Phase 2a monotherapy missed primary endpoint (-1.52% vs -0.26% placebo weight loss), but combination with semaglutide showed 13.2% weight loss vs 10.25% semaglutide alone (p=0.0372), with reduced weight rebound post-treatment (17.8% vs 37.3%).
Business: Phase 2a Results verify on EDGAR → -
high
Strategic pivot announced alongside 25% workforce reduction (16 to 12 employees), removal of broader GPCR platform language, and initiation of IV dosing expansion study at higher doses (400mg/600mg) after subcutaneous monotherapy underperformed.
Business & MD&A verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (TRV 10-Q) is open in full — no account needed.
Partner
Trade SKYE commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · Jun 5, 2026 · How we verify